These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

119 related items for PubMed ID: 24800837

  • 1. Identification of responders to sorafenib in hepatocellular carcinoma: is tumor volume measurement the way forward?
    Bargellini I, Scionti A, Mismas V, Masi G, Vivaldi C, Bartolozzi C, Sacco R.
    Oncology; 2014; 86(4):191-8. PubMed ID: 24800837
    [Abstract] [Full Text] [Related]

  • 2. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
    Gavanier M, Ayav A, Sellal C, Orry X, Claudon M, Bronowicki JP, Laurent V.
    Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
    Kawaoka T, Aikata H, Murakami E, Nakahara T, Naeshiro N, Tanaka M, Honda Y, Miyaki D, Nagaoki Y, Takaki S, Hiramatsu A, Waki K, Takahashi S, Chayama K.
    Oncology; 2012 Jan; 83(4):192-200. PubMed ID: 22890083
    [Abstract] [Full Text] [Related]

  • 4. Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma.
    Takada J, Hidaka H, Nakazawa T, Kondo M, Numata K, Tanaka K, Matsunaga K, Okuse C, Kobayashi S, Morimoto M, Ohkawa S, Koizumi W.
    BMC Res Notes; 2015 Oct 26; 8():609. PubMed ID: 26502722
    [Abstract] [Full Text] [Related]

  • 5. Alternative Response Criteria (Choi, European association for the study of the liver, and modified Response Evaluation Criteria in Solid Tumors [RECIST]) Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Ronot M, Bouattour M, Wassermann J, Bruno O, Dreyer C, Larroque B, Castera L, Vilgrain V, Belghiti J, Raymond E, Faivre S.
    Oncologist; 2014 Apr 26; 19(4):394-402. PubMed ID: 24652387
    [Abstract] [Full Text] [Related]

  • 6. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
    Meyer T, Palmer DH, Cheng AL, Hocke J, Loembé AB, Yen CJ.
    Liver Int; 2017 Jul 26; 37(7):1047-1055. PubMed ID: 28066978
    [Abstract] [Full Text] [Related]

  • 7. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
    Edeline J, Boucher E, Rolland Y, Vauléon E, Pracht M, Perrin C, Le Roux C, Raoul JL.
    Cancer; 2012 Jan 01; 118(1):147-56. PubMed ID: 21713764
    [Abstract] [Full Text] [Related]

  • 8. Prognostic value of perfusion CT in hepatocellular carcinoma treatment with sorafenib: comparison with mRECIST in longitudinal follow-up.
    Kaufmann S, Thaiss WM, Schulze M, Bitzer M, Lauer U, Nikolaou K, Horger M.
    Acta Radiol; 2018 Jul 01; 59(7):765-772. PubMed ID: 28927298
    [Abstract] [Full Text] [Related]

  • 9. Unresectable hepatocellular carcinoma: MR imaging after intraarterial therapy. Part II. Response stratification using volumetric functional criteria after intraarterial therapy.
    Bonekamp S, Halappa VG, Geschwind JF, Li Z, Corona-Villalobos CP, Reyes D, Bhagat N, Cosgrove DP, Pawlik TM, Mezey E, Eng J, Kamel IR.
    Radiology; 2013 Aug 01; 268(2):431-9. PubMed ID: 23616632
    [Abstract] [Full Text] [Related]

  • 10. Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.
    Personeni N, Bozzarelli S, Pressiani T, Rimassa L, Tronconi MC, Sclafani F, Carnaghi C, Pedicini V, Giordano L, Santoro A.
    J Hepatol; 2012 Jul 01; 57(1):101-7. PubMed ID: 22414760
    [Abstract] [Full Text] [Related]

  • 11. Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Nakazawa T, Hidaka H, Takada J, Okuwaki Y, Tanaka Y, Watanabe M, Shibuya A, Minamino T, Kokubu S, Koizumi W.
    Eur J Gastroenterol Hepatol; 2013 Jun 01; 25(6):683-9. PubMed ID: 23395995
    [Abstract] [Full Text] [Related]

  • 12. Inter-operator variability and source of errors in tumour response assessment for hepatocellular carcinoma treated with sorafenib.
    Tovoli F, Renzulli M, Negrini G, Brocchi S, Ferrarini A, Andreone A, Benevento F, Golfieri R, Morselli-Labate AM, Mastroroberto M, Badea RI, Piscaglia F.
    Eur Radiol; 2018 Sep 01; 28(9):3611-3620. PubMed ID: 29633000
    [Abstract] [Full Text] [Related]

  • 13. Radiological-pathological analysis of WHO, RECIST, EASL, mRECIST and DWI: Imaging analysis from a prospective randomized trial of Y90 ± sorafenib.
    Vouche M, Kulik L, Atassi R, Memon K, Hickey R, Ganger D, Miller FH, Yaghmai V, Abecassis M, Baker T, Mulcahy M, Nayar R, Lewandowski RJ, Salem R.
    Hepatology; 2013 Nov 01; 58(5):1655-66. PubMed ID: 23703789
    [Abstract] [Full Text] [Related]

  • 14. Clinical features associated with radiological response to sorafenib in unresectable hepatocellular carcinoma: a large multicenter study in Japan.
    Takeda H, Nishikawa H, Osaki Y, Tsuchiya K, Joko K, Ogawa C, Taniguchi H, Orito E, Uchida Y, Izumi N, Japanese Red Cross Liver Study Group.
    Liver Int; 2015 May 01; 35(5):1581-9. PubMed ID: 24836552
    [Abstract] [Full Text] [Related]

  • 15. Decrease in tumor enhancement on contrast-enhanced CT is associated with improved survival in patients with hepatocellular carcinoma treated with Sorafenib.
    Patchett N, Furlan A, Marsh JW.
    Jpn J Clin Oncol; 2016 Sep 01; 46(9):839-44. PubMed ID: 27317737
    [Abstract] [Full Text] [Related]

  • 16. Hepatocellular carcinoma enhancement on contrast-enhanced CT and MR imaging: response assessment after treatment with sorafenib: preliminary results.
    Salvaggio G, Furlan A, Agnello F, Cabibbo G, Marin D, Giannitrapani L, Genco C, Midiri M, Lagalla R, Brancatelli G.
    Radiol Med; 2014 Apr 01; 119(4):215-21. PubMed ID: 24297581
    [Abstract] [Full Text] [Related]

  • 17. Prospective comparison of prognostic values of modified Response Evaluation Criteria in Solid Tumours with European Association for the Study of the Liver criteria in hepatocellular carcinoma following chemoembolisation.
    Kim BK, Kim KA, Park JY, Ahn SH, Chon CY, Han KH, Kim SU, Kim MJ.
    Eur J Cancer; 2013 Mar 01; 49(4):826-34. PubMed ID: 22995582
    [Abstract] [Full Text] [Related]

  • 18. Complete and Sustained Off-Therapy Response to Sorafenib in Advanced Hepatocellular Carcinoma.
    Maida M, Macaluso FS, Valenza F, Virdone R.
    J Gastrointestin Liver Dis; 2016 Jun 01; 25(2):253-5. PubMed ID: 27308660
    [Abstract] [Full Text] [Related]

  • 19. Treatment of hepatocellular carcinoma combining sorafenib and transarterial locoregional therapy: state of the science.
    Weintraub JL, Salem R.
    J Vasc Interv Radiol; 2013 Aug 01; 24(8):1123-34. PubMed ID: 23562168
    [Abstract] [Full Text] [Related]

  • 20. EASL- and mRECIST-evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma.
    Liu L, Wang W, Chen H, Zhao Y, Bai W, Yin Z, He C, Jia J, Yang M, Xia J, Fan D, Han G.
    Clin Cancer Res; 2014 Mar 15; 20(6):1623-31. PubMed ID: 24493832
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.